Concurrent Exercise Training (T2D)

June 1, 2026 updated by: Ahmad Saied Mohammad, Prince Sattam Bin Abdulaziz University

The Impact of Morning Versus Evening Concurrent High-Intensity Interval Training and Resistance Training on Glycemic Control in in Men With Type 2 Diabetes Mellitus: A Randomized Controlled Trial

The goal of this clinical trial is to investigate the influence of morning versus evening concurrent training consisting of high-intensity interval training and resistance training on glycemic control in men with type 2 diabetes mellitus. The main questions it aims to answer are:

• Which time is best for concurrent exercise training in diabetic patients, morning or evening? Researchers will compare morning versus evening concurrent training consisting of HIIT and RT on glycemic control in men with type 2 diabetes mellitus.

Participants will:

  • Perform concurrent training consisting of high-intensity interval training and resistance training for 12 weeks
  • Visit the clinic before and after the 12-week experimental period for checkups and tests

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

60

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • men aged 40-60 years with a diagnosis of T2D
  • HbA1c levels between 7.0% and 9.0%
  • treatment with oral hypoglycemic agents for at least 6 months
  • a BMI <30 kg/m²
  • a physically inactive

Exclusion Criteria:

  • current insulin therapy
  • a cardiovascular event within the previous 6 months
  • cardiovascular, respiratory or musculoskeletal conditions that could limit participation in exercise training
  • body weight instability

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Morning concurrent training (amCT)
will perform combined HIIT and RT between 06:00 and 09:00
Behavioral: Exercise
Morning concurrent high-intensity interval training and resistance training
Experimental: Evening concurrent training (pmCT)
will perform combined HIIT and RT between 16:00 and 19:00
Behavioral: exercise
evening concurrent high-intensity interval training and resistance training between 16:00 and 19:00
No Intervention: The control group (CON)
no exercise program

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
glycemic control
Time Frame: baseline and at 12 weeks.
HbA1c
baseline and at 12 weeks.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
lipid profile
Time Frame: baseline and at 12 weeks
total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides
baseline and at 12 weeks
cardiorespiratory fitness
Time Frame: at baseline and at 12 weeks
VO2peak
at baseline and at 12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Prince Sattam Bin Abdulaziz University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

June 1, 2026

Primary Completion (Estimated)

September 1, 2026

Study Completion (Estimated)

October 1, 2026

Study Registration Dates

First Submitted

June 1, 2026

First Submitted That Met QC Criteria

June 1, 2026

First Posted (Actual)

June 5, 2026

Study Record Updates

Last Update Posted (Actual)

June 5, 2026

Last Update Submitted That Met QC Criteria

June 1, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CT 2026
  • 2025/03/33413 (Other Grant/Funding Number: Prince Sattam bin Abdulaziz University)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

on request from the PA

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Typ 2 Diabetes

Clinical Trials on Exercise

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Rwanda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe